A Study in Healthy People to Test Whether Erythromycin Influences the Amount of BI 1291583 in the Blood
Status:
COMPLETED
Trial end date:
2025-09-09
Target enrollment:
Participant gender:
Summary
The main objective of this trial is to investigate the effect of erythromycin, a moderate CYP3A4 inhibitor on the pharmacokinetics of BI 1291583 at steady state.